文献速递预防保健、筛查与疫苗慢病管理

牛津-阿斯利康ChAdOx1-S疫苗接种后动脉事件、静脉血栓栓塞、血小板减少与出血:丹麦和挪威人群队列研究

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.
PubMed 文献 · BMJ · 2021-05-05

结果显示静脉血栓栓塞事件发生率升高(标准化发病比1.97),包括脑静脉血栓形成(标准化发病比20.25),但绝对风险较小;动脉事件、血小板减少/凝血障碍及出血的结果总体令人安心。

要点

  • 接种ChAdOx1-S后28天内静脉血栓栓塞事件发生率高于一般人群预期,标准化发病比为1.97。
  • 脑静脉血栓形成的标准化发病比达20.25,每10万剂疫苗接种超额发生2.5例。
  • 动脉事件、血小板减少/凝血障碍及出血的发生率与一般人群相比无显著升高,结果总体令人安心。

核心结论

  • 接种ChAdOx1-S后静脉血栓栓塞事件(包括脑静脉血栓形成)发生率升高,但绝对风险较小,其余安全性结局总体令人安心。

研究设计与样本

  • 基于丹麦和挪威全国医疗登记的人群队列研究,纳入2021年2月9日至3月11日接种首剂ChAdOx1-S的18-65岁人群,以两国一般人群作为对照队列。

主要发现

  • 接种后28天内动脉事件的标准化发病比为0.97(95%CI 0.77-1.20)。
  • 静脉血栓栓塞事件观察59例,预期30例,标准化发病比1.97(95%CI 1.50-2.54),每10万剂疫苗接种超额11例(95%CI 5.6-17.0)。
  • 脑静脉血栓形成标准化发病比20.25(95%CI 8.14-41.73),每10万剂疫苗接种超额2.5例(95%CI 0.9-5.2)。
  • 任何血小板减少/凝血障碍的标准化发病比为1.52(95%CI 0.97-2.25),任何出血的标准化发病比为1.23(95%CI 0.97-1.55);接种队列观察15例死亡,预期44例。

关键数值与推荐

  • 静脉血栓栓塞事件标准化发病比1.97(95%CI 1.50-2.54),每10万剂疫苗接种超额11例(95%CI 5.6-17.0)。
  • 脑静脉血栓形成标准化发病比20.25(95%CI 8.14-41.73),每10万剂疫苗接种超额2.5例(95%CI 0.9-5.2)。
  • 动脉事件标准化发病比0.97(95%CI 0.77-1.20);血小板减少/凝血障碍标准化发病比1.52(95%CI 0.97-2.25);出血标准化发病比1.23(95%CI 0.97-1.55)。

临床怎么用

  • 接种ChAdOx1-S后应关注静脉血栓栓塞事件(包括脑静脉血栓形成)的罕见但升高的风险,尤其在新发神经系统症状或血栓表现时。
  • 接种后血小板减少/凝血障碍及出血的轻微升高可能受疫苗接种者监测增强影响,临床评估时需结合个体情况。
  • 决策时应权衡疫苗已证实的获益、所在国家疫情背景及研究结果外推的局限性。

局限性

  • 研究结果的外推性存在局限性,需结合具体国家背景解读。
  • 血小板减少/凝血障碍及出血的轻微升高可能受疫苗接种者监测增强的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess rates of cardiovascular and haemostatic events in the first 28 days after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S in Denmark and Norway and to compare them with rates observed in the general populations. DESIGN: Population based cohort study. SETTING: Nationwide healthcare registers in Denmark and Norway. PARTICIPANTS: All people aged 18-65 years who received a first vaccination with ChAdOx1-S from 9 February 2021 to 11 March 2021. The general populations of Denmark (2016-18) and Norway (2018-19) served as comparator cohorts. MAIN OUTCOME MEASURES: Observed 28 day rates of hospital contacts for incident arterial events, venous thromboembolism, thrombocytopenia/coagulation disorders, and bleeding among vaccinated people compared with expected rates, based on national age and sex specific background rates from the general populations of the two countries. RESULTS: The vaccinated cohorts comprised 148 792 people in Denmark (median age 45 years, 80% women) and 132 472 in Norway (median age 44 years, 78% women), who received their first dose of ChAdOx1-S. Among 281 264 people who received ChAdOx1-S, the standardised morbidity ratio for arterial events was 0.97 (95% confidence interval 0.77 to 1.20). 59 venous thromboembolic events were observed in the vaccinated cohort compared with 30 expected based on the incidence rates in the general population, corresponding to a standardised morbidity ratio of 1.97 (1.50 to 2.54) and 11 (5.6 to 17.0) excess events per 100 000 vaccinations. A higher than expected rate of cerebral venous thrombosis was observed: standardised morbidity ratio 20.25 (8.14 to 41.73); an excess of 2.5 (0.9 to 5.2) events per 100 000 vaccinations. The standardised morbidity ratio for any thrombocytopenia/coagulation disorders was 1.52 (0.97 to 2.25) and for any bleeding was 1.23 (0.97 to 1.55). 15 deaths were observed in the vaccine cohort compared with 44 expected. CONCLUSIONS: Among recipients of ChAdOx1-S, increased rates of venous thromboembolic events, including cerebral venous thrombosis, were observed. For the remaining safety outcomes, results were largely reassuring, with slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, which could be influenced by increased surveillance of vaccine recipients. The absolute risks of venous thromboembolic events were, however, small, and the findings should be interpreted in the light of the proven beneficial effects of the vaccine, the context of the given country, and the limitations to the generalisability of the study findings.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021. PMID: 33952445. doi:10.1136/bmj.n1114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。